HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. Tropical spastic paraplegia
Conditions
Interventions
Intervention 1: Intervention group: Daily administration of two10-mg capsules ofDalfampridine for 2 months. The drug company is Zahravi,. Intervention 2: Control group: Control group: Daily administra
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Positive serology for Human T-cell Lymphotropic Virus Type-1 (HTLV-1) Occurrence of spastic paraparesia Existence of anti HTLV-1 antibody in cerebrospinal fluid Rule out of other etiologies of spastic paraparesia Motor Disability Grading (MDG) less than 9 Informed consent for participating in the study
Exclusion criteria
Exclusion criteria: Existence of other active and latent infections Receiving other drug which influence immune system Existence of any history of seizures or epilepsy or other seizure disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Medical Research Council (MRC) Scale for Muscle Strength. Timepoint: At the begging of study and months of 1 and 2. Method of measurement: Physical examination.;Spasticity score with Ashworth scale. Timepoint: At the begging of study and months of 1 and 2. Method of measurement: Physical examination.;Motor Disability score with Osame Motor Disability Score. Timepoint: At the begging of study and months of 1 and 2. Method of measurement: Physical examination.;T25FW:Timed 25 foot walk. Timepoint: At the begging of study and months of 1 and 2. Method of measurement: Physical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Reza Boostani
Mashhad University of Medical Sciences
Outcome results
None listed